Skip to main content

Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache

  • J A de Ru (a1) and J Buwalda (a1)

To describe our results with botulinum toxin type A injection for headache in carefully selected patients, and to present the rationale behind this therapy.


Tertiary referral centre.

Patients and methods:

This article describes a case series of 10 consecutive patients with frontally localised headache, whose pain worsened when pressure was applied at the orbital rim near the supratrochlear nerve. The patients received a local anaesthetic nerve block with Xylocaine 2 per cent at this site. If this reduced the pain, they were then offered treatment with botulinum toxin.


Injection with 12.5 IU of botulinum toxin A into the corrugator supercilii muscle on both sides (a total of 25 IU).

Main outcome measure:

Pain severity scoring by the patients, ranging from zero (no pain) to 10 (severe pain) on a verbal scale.


Following injection, all patients had less pain for approximately two months. This treatment did not appear to have lasting side effects.


Xylocaine injection is a good predictor of the effectiveness of botulinum toxin injection into the corrugator muscle as treatment of frontally localised headache. We hypothesise that this pain is caused by entrapment of the supratrochlearis nerve in the corrugator muscle. Furthermore, we found botulinum toxin injection to be a safe and effective means of achieving pain relief in this patient group.

Corresponding author
Address for correspondence: Dr J A de Ru, ENT Surgeon, Department of Otolaryngology-Head Neck Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Fax: 0031 302541922 E-mail:
Hide All
1 Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005;45:315–24
2 Pakalnis A, Couch J. Headache therapy with botulinum toxin: form over substance. Arch Neurol 2008;65:149–51
3 Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293307
4 Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005;80:1126–37
5 Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA 1998;279:381–3
6 Padberg M, De Bruijn SFTM, De Haan RJ, Tavy DLJ. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004;24:675–80
7 Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R. Treatment of tension-type headache with botulinum toxin type A: a double blind, placebo-controlled study. Headache 2000;40:300–5
8 Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24(suppl 1):9160
9 Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000;123:669–76
10 Barrientos N, Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 2003;4:146–51
11 Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double blind, placebo-controlled multicenter study. Pain 2004;109:110–4
12 Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW. Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005;45:308–14
13 Ashkenazi A, Silberstein SD. Botulinum toxin and other new approaches to migraine therapy. Ann Rev Med 2004;55:505–8
14 Ashkenazi A, Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes. Arch Neurol 2008;65:146–9
15 Roach ES. Questioning botulinum toxin for headache: reality or illusion. Arch Neurol 2008;65:151–2
16 Dirnberger F, Becker K. Surgical treatment of migraine headaches by corrugator muscle resection. Plast Reconstr Surg 2004;114:652–7
17 Bearden WH, Anderson RL. Corrugator superciliaris muscle excision for tension and migraine headaches. Ophthal Plast Reconstr Surg 2005;21:418–22
18 Guyuron B, Kriegler JS, Davis J, Amini SB. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg 2005;115:19
19 Guyuron B, Varghai A, Michelow BJ, Thomas T, Davis J. Corrugator supercilii muscle resection and migraine headaches. Plast Reconstr Surg 2000;106:429–34
20 Guyuron B, Tucker T, Davis J. Surgical treatment of migraine headaches. Plast Reconstr Surg 2002;109:2183–9
21 Schwedt TJ, Hentz JG, Dodick DW. Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum for migraine. Cephalalgia 2007;27:528–34
22 Evers S, Olesen J. Reply: letters to the editor. Cephalalgia 2007;27:468
23 Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder J-M. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001;41:658–64
24 Behmand RA, Tucker T, Guyuron B. Single-site botulinum toxin type A injection for elimination of migraine trigger points. Headache 2003;43:1085–9
25 Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 2004;44:801–5
26 Mosser S, Guyuron B, Janis J, Rohrich R. The anatomy of the greater occipital nerve: implications for the etiology of migraine headaches. Plast Reconstr Surg 2004;113:693–7
27 Fernández de las Peñas C, Cuadrado ML, Arendt Nielsen L, Simons DG, Pareja JA. Myofascial trigger points and sensitization: an updated pain model for tension-type headache. Cephalalgia 2007;27:383–93
28 Bendtsen L. Central sensitization in tension-type headache: possible patho-physiological mechanisms. Cephalalgia 2000;29:486–50
29 McPartland JM, Simons DG. Myofascial trigger points: translating molecular theory into manual therapy. J Man Manipul Therapy 2006;14:232–9
30 Ho K-Y, Tan K-H. Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review. Eur J Pain 2007;11:519–27
31 Muehlberger T, Fisher P, Lehnhardt M. The anatomy of the surgical treatment of migraine [in German]. Zentralbl Chir 2005;130:288–92
32 Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol 2007;52:1331
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The Journal of Laryngology & Otology
  • ISSN: 0022-2151
  • EISSN: 1748-5460
  • URL: /core/journals/journal-of-laryngology-and-otology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 1
Total number of PDF views: 12 *
Loading metrics...

Abstract views

Total abstract views: 116 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 18th November 2017. This data will be updated every 24 hours.